Updated:
Scilex Holding Company
Scilex Holding Company (SCLX) is a Nasdaq-listed firm focused on non-opioid pain management, led by CEO Henry Ji.
Scilex Holding Company
Scilex Holding Company (Nasdaq: SCLX) is led by Henry Ji, who also co-founded Sorrento Therapeutics and has served as Scilex's Executive Chairman and CEO since March 2019. The firm is headquartered in Palo Alto, California, with an additional office in Singapore. Its wealth origin is not publicly disclosed; the company generates revenue from commercialized pharmaceutical products. Scilex focuses on acquiring, developing, and commercializing non-opioid pain management treatments. Its portfolio includes three FDA-approved products: ZTlido (lidocaine topical system) for post-herpetic neuralgia, GLOPERBA for gout flares, and ELYXYB for migraine. The pipeline features SEMDEXA (SP-102) for sciatica, which completed a Phase 3 trial, SP-103 for acute low back pain, and SP-104 for fibromyalgia. The company also formed a joint venture, Scilex Bio, with IPMC Company to develop a reversible MAO-B inhibitor for obesity and Alzheimer's disease. Scilex operates primarily in the U.S., with international collaborations. The company is publicly traded on Nasdaq, with an unspecified number of employees. Henry Ji serves as Executive Chairman, CEO, and President. The leadership team includes Stephen Ma (COO and CFO), Dmitri Lissin (Interim Chief Medical Officer), and Suketu Desai (Interim Chief Technical Officer). In May 2026, Scilex announced a dividend of Semnur Pharmaceuticals common stock to its shareholders, with a record date of June 1, 2026. Scilex's structural differentiator is its status as a publicly traded holding company that operates through wholly-owned subsidiaries dedicated to non-opioid pain management. This structure allows it to fund development through public markets while maintaining a focused pipeline of both marketed products and clinical-stage candidates.
General information
Firm type
other
Year founded
—
AUM
Undisclosed
Location
Region
North America
Country
United States
City
Palo Alto
Corporate office
Palo Alto, CA, United States
Additional offices
Singapore
Principals
Henry Ji
Executive Chairman, Chief Executive Officer and President
Stephen Ma
Chief Operating Officer, Chief Financial Officer and Senior Vice President
Dmitri Lissin
Interim Chief Medical Officer and Senior Vice President, Clinical Development and Medical Affairs
Suketu D. Desai
Interim Chief Technical Officer and Senior Vice President, Chemistry, Manufacturing and Controls, Regulatory CMC, and Quality Assurance
Khemani
SVP, Chief Commercial Officer
Sector focus
Frequently asked questions
Who runs investment decisions at Scilex Holding Company?
Henry Ji serves as Executive Chairman, Chief Executive Officer, and President of Scilex, overseeing corporate strategy and product development. Stephen Ma handles financial operations as COO and CFO. The five-person board of directors includes Ji, Dorman Followwill, Yue Alexander Wu, Jay Chun, and Ma.
How does Scilex generate revenue?
Scilex is a revenue-generating company through sales of its three FDA-approved non-opioid products: ZTlido (lidocaine patch for post-herpetic neuralgia), GLOPERBA (for gout flares), and ELYXYB (for migraine). The firm acquires product candidates and builds a pipeline in chronic pain management.
Is Scilex structured as a family office or an operating company?
Scilex is a publicly traded holding company (Nasdaq: SCLX) that operates through wholly-owned subsidiaries Scilex Pharmaceuticals and Semnur Pharmaceuticals. It also holds a joint venture, Scilex Bio, for neurodegenerative disease treatments.
What investment stages does Scilex typically target?
Scilex acquires and develops late-stage and commercial-stage non-opioid pain management products. Its strategy includes in-licensing or acquiring approved drugs and advancing clinical candidates through FDA processes, such as SEMDEXA which completed Phase 3 trials.
Which sectors does Scilex explicitly avoid?
Scilex focuses exclusively on non-opioid pain management and adjacent therapeutic areas. Its portfolio avoids opioids and targets treatments for acute and chronic pain, migraine, gout, sciatica, and fibromyalgia.
How is Scilex related to Sorrento Therapeutics?
Henry Ji co-founded Sorrento Therapeutics and has served as its CEO and Chairman. Scilex was originally a subsidiary of Sorrento and became a separate public company, though Ji leads both entities. The exact corporate relationship is not fully detailed in public filings.
What is Scilex's known posture on co-investments alongside external GPs?
Scilex does not publicly disclose involvement in co-investments with external general partners. Its business model centers on organic product development and acquisitions within the pharmaceutical sector rather than financial investments.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: